Palisade Bio, Inc. (PALI) Stock Price & Analysis
Palisade Bio, Inc. (PALI) rose 2.20% to USD 2.09 as of September 8, 2026 at 06:21 UTC, according to Nexqual real-time market data.
PALI last closed at USD 2.05; the session ranged USD 2–2.12 on volume of 1,755,319 shares. Market capitalization is $364.23M, with a 52-week range of USD 0.53–2.86 (NCM). Source: Nexqual, September 8, 2026 at 06:21 UTC.
Key Statistics (as of September 8, 2026 at 06:21 UTC)
| Price | USD 2.09 |
|---|---|
| Change | ▲ 2.20% (up) |
| Previous Close | USD 2.05 |
| Open | USD 2.03 |
| Day Range | USD 2 – 2.12 |
| 52-Week Range | USD 0.53 – 2.86 |
| Volume | 1,755,319 shares |
| Market Cap | $364.23M |
| Exchange | NCM |
Technical Analysis (PALI)
Nexqual's technical model rates PALI "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 06:21 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.27 (neutral) |
| vs SMA50 | Above (USD 2.03) |
| MACD | 0 (positive) |
Analyst Ratings (PALI)
Wall Street analysts rate PALI "Strong Buy" based on 9 analysts, with a mean price target of USD 10.22 (range USD 5–25), per Nexqual as of September 8, 2026 at 06:21 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 10.22 |
| High Target | USD 25 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (PALI)
| EPS Estimate | USD -0.06 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.05 vs est -0.05 ▲ beat |
| 2025-09-30 | USD -0.38 vs est -0.27 ▼ miss |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
Financials & Fundamentals (PALI)
| Total Revenue | $500,000 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -2339.60% |
| Profit Margin | +0.00% |
| ROE | -51.37% |
| Current Ratio | 24.26 |
| Total Cash | $125.17M |
| Total Debt | $0 |
| Free Cash Flow | $-8.65M |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
Financial Health Score (PALI)
Nexqual rates Palisade Bio, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 06:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $125M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$18M |
| Efficiency | Critical — ROE -51%, ROA -33.0% |
Ownership (PALI)
| Insider Ownership | +1.69% |
|---|---|
| Institutional Ownership | +101.50% |
| Shares Outstanding | 174.27M |
| Float | 138.85M |
| Short % of Float | +19.17% |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
Leadership (PALI)
Palisade Bio, Inc. is led by J. D. Finley (age 67), CEO, CFO & Director, per Nexqual as of September 8, 2026 at 06:21 UTC.
| CEO, CFO & Director | J. D. Finley (age 67) |
|---|---|
| President & Chief Medical Officer | Mitchell Lawrence Jones (age 48) |
Major Backers & Investors (PALI)
Notable institutional backers of Palisade Bio, Inc. include Soleus Capital Management, L.P., B Group, Inc. , Ameriprise Financial, Inc., according to Nexqual as of September 8, 2026 at 06:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Soleus Capital Management, L.P. | 7.5% |
| B Group, Inc. | 6.55% |
| Ameriprise Financial, Inc. | 6.36% |
| Jupiter Topco LLC | 6.13% |
| Octagon Capital Advisors LP | 5.9% |
| Perceptive Advisors Llc | 4.83% |
| RA Capital Management, L.P. | 4.09% |
| Franklin Resources, Inc. | 3.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.05% |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
From Palisade Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.
- Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Partnerships
- The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.46 | ▲ 2.93% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.55 | ▼ 1.54% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 7.26 | ▲ 7.72% |
| REVB | Revelation Biosciences, Inc. | USD 1.01 | ▲ 1% |
| RNAZ | TransCode Therapeutics, Inc. | USD 2.06 | ▲ 2.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:21 UTC. This page is informational and not investment advice.